• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

胰高血糖素样肽-1受体激动剂有潜力彻底改变2型糖尿病患者糖化血红蛋白（A1C）目标水平的实现情况——那么为何其使用率如此之低呢？

Glucagon-Like Peptide 1 Receptor Agonists Have the Potential to Revolutionize the Attainment of Target A1C Levels in Type 2 Diabetes-So Why Is Their Uptake So Low?

作者信息

King Aaron, Miller Eden M

机构信息

MedFirst at the Quarry, San Antonio, TX.

Diabetes and Obesity Care, Bend, OR.

出版信息

Clin Diabetes. 2023 Spring;41(2):226-238. doi: 10.2337/cd22-0027. Epub 2022 Nov 3.

DOI:10.2337/cd22-0027
PMID:37092151
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10115618/
Abstract

A target A1C of <7% is the recommended goal for most people with type 2 diabetes. However, many are not achieving this target with their current treatment. Glucagon-like peptide 1 (GLP-1) receptor agonists are highly efficacious in achieving glycemic control and could aid primary care providers (PCPs) in getting patients to their A1C target. However, despite their potential, use of GLP-1 receptor agonists in the primary care setting is limited. This review provides guidance for PCPs on how to help patients achieve their glycemic target and overcome perceived barriers of GLP-1 receptor agonist use, with the overall goal of improving PCP confidence in prescribing these agents.

摘要

糖化血红蛋白（A1C）目标值<7%是大多数2型糖尿病患者的推荐目标。然而，许多患者目前的治疗方案并未达到这一目标。胰高血糖素样肽1（GLP-1）受体激动剂在实现血糖控制方面非常有效，有助于初级保健提供者（PCP）帮助患者达到A1C目标。然而，尽管GLP-1受体激动剂具有潜力，但在初级保健环境中的使用仍然有限。本综述为初级保健提供者提供指导，帮助患者实现血糖目标并克服使用GLP-1受体激动剂的认知障碍，总体目标是提高初级保健提供者开具这些药物的信心。

相似文献

1
Glucagon-Like Peptide 1 Receptor Agonists Have the Potential to Revolutionize the Attainment of Target A1C Levels in Type 2 Diabetes-So Why Is Their Uptake So Low?胰高血糖素样肽-1受体激动剂有潜力彻底改变2型糖尿病患者糖化血红蛋白（A1C）目标水平的实现情况——那么为何其使用率如此之低呢？
Clin Diabetes. 2023 Spring;41(2):226-238. doi: 10.2337/cd22-0027. Epub 2022 Nov 3.
2
Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE).在 2 型糖尿病患者中比较每周一次胰高血糖素样肽-1 受体激动剂（OW GLP-1RAs）与二肽基肽酶-4 抑制剂（DPP-4is）的降糖和减重效果的真实世界疗效（RELATE）。
Clin Drug Investig. 2024 Apr;44(4):271-284. doi: 10.1007/s40261-024-01354-2. Epub 2024 Mar 20.
3
Real-World Glycemic Control from GLP-1RA Therapy with and Without Concurrent Insulin in Patients with Type 2 Diabetes.GLP-1RA 治疗伴有或不伴有胰岛素的 2 型糖尿病患者的真实世界血糖控制情况。
J Manag Care Spec Pharm. 2017 Mar;23(3):267-275. doi: 10.18553/jmcp.2017.16334. Epub 2017 Feb 6.
4
Healthcare professionals' perceptions and management of obesity & knowledge of glucagon, GLP-1, GIP receptor agonists, and dual agonists.医疗保健专业人员对肥胖症的认知与管理以及对胰高血糖素、胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽受体激动剂和双重激动剂的了解。
Obes Sci Pract. 2024 May 4;10(3):e756. doi: 10.1002/osp4.756. eCollection 2024 Jun.
5
Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists.GLP-1 受体激动剂作用机制与体重减轻和维持的关系。
Adv Ther. 2021 Jun;38(6):2821-2839. doi: 10.1007/s12325-021-01710-0. Epub 2021 May 11.
6
COMPARING CLINICAL OUTCOMES AND COSTS FOR DIFFERENT TREATMENT INTENSIFICATION APPROACHES IN PATIENTS WITH TYPE 2 DIABETES UNCONTROLLED ON BASAL INSULIN: ADDING GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS VERSUS ADDING RAPID-ACTING INSULIN OR INCREASING BASAL INSULIN DOSE.比较基础胰岛素治疗血糖控制不佳的2型糖尿病患者不同强化治疗方法的临床结局和成本：加用胰高血糖素样肽-1受体激动剂与加用速效胰岛素或增加基础胰岛素剂量的比较
Endocr Pract. 2017 Nov;23(11):1316-1324. doi: 10.4158/EP171769.OR. Epub 2017 Aug 17.
7
GLP-1 receptor agonists and HBA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials.GLP-1 受体激动剂和糖化血红蛋白 <7%在 2 型糖尿病中的目标：随机对照试验的荟萃分析。
Curr Med Res Opin. 2011 Aug;27(8):1519-28. doi: 10.1185/03007995.2011.590127. Epub 2011 Jun 13.
8
Adherence to NICE guidance on glucagon-like peptide-1 receptor agonists among patients with type 2 diabetes mellitus: an evaluation using the Clinical Practice Research Datalink.2型糖尿病患者对胰高血糖素样肽-1受体激动剂相关英国国家卫生与临床优化研究所指南的依从性：一项使用临床实践研究数据链的评估
Curr Med Res Opin. 2016;32(1):49-60. doi: 10.1185/03007995.2015.1101372. Epub 2015 Nov 19.
9
Influence of Treatment Intensification on A1c in Patients with Suboptimally Controlled Type 2 Diabetes After 2 Oral Antidiabetic Agents.两种口服降糖药治疗后血糖控制不佳的 2 型糖尿病患者强化治疗对 A1c 的影响。
J Manag Care Spec Pharm. 2019 Mar;25(3):314-322. doi: 10.18553/jmcp.2019.25.3.314.
10
The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide.短效和长效胰高血糖素样肽-1激动剂在2型糖尿病管理中的价值：艾塞那肽的应用经验
Curr Med Res Opin. 2016;32(1):61-76. doi: 10.1185/03007995.2015.1103214. Epub 2015 Nov 11.

引用本文的文献

1
GLP-1 receptor agonists and pancreatic beta cell apoptosis in diabetes mellitus: a systematic review and meta-analysis of preclinical studies.胰高血糖素样肽-1受体激动剂与糖尿病中的胰腺β细胞凋亡：一项临床前研究的系统评价和荟萃分析
Front Clin Diabetes Healthc. 2025 Aug 27;6:1579961. doi: 10.3389/fcdhc.2025.1579961. eCollection 2025.
2
Beyond GLP-1: efficacy and safety of dual and triple incretin agonists in personalized type 2 diabetes care-a systematic review and network meta-analysis.超越胰高血糖素样肽-1：双重和三重肠促胰岛素激动剂在2型糖尿病个性化治疗中的疗效和安全性——一项系统评价与网状Meta分析
Acta Diabetol. 2025 Jun 5. doi: 10.1007/s00592-025-02534-y.
3
Impact of Glucagon-Like Peptide-1 Receptor Agonist Exposure on Gastrointestinal Outcomes Among ICU Patients: A Multicenter Matched Cohort Study.胰高血糖素样肽-1受体激动剂暴露对重症监护病房患者胃肠道结局的影响：一项多中心匹配队列研究
Crit Care Explor. 2025 May 14;7(5):e1263. doi: 10.1097/CCE.0000000000001263. eCollection 2025 May 1.
4
Continuous glucose monitoring guides glucagon-like peptide 1-based therapy use and optimization in people with type 2 diabetes.持续葡萄糖监测指导2型糖尿病患者使用和优化基于胰高血糖素样肽1的治疗。
J Family Med Prim Care. 2025 Feb;14(2):790-795. doi: 10.4103/jfmpc.jfmpc_773_24. Epub 2025 Feb 21.
5
GLP-1 Receptor Agonists: Beyond Diabetes-What the Neurosurgeon Needs to Know.胰高血糖素样肽-1受体激动剂：超越糖尿病——神经外科医生需要了解的内容
Neurosurg Pract. 2024 Jun 27;5(3):e00098. doi: 10.1227/neuprac.0000000000000098. eCollection 2024 Sep.
6
Pancreatitis Risk Associated with GLP-1 Receptor Agonists, Considered as a Single Class, in a Comorbidity-Free Subgroup of Type 2 Diabetes Patients in the United States: A Propensity Score-Matched Analysis.在美国2型糖尿病无合并症亚组中，将胰高血糖素样肽-1受体激动剂视为单一类别时其胰腺炎风险：一项倾向评分匹配分析
J Clin Med. 2025 Feb 1;14(3):944. doi: 10.3390/jcm14030944.
7
Recent Advances and Therapeutic Benefits of Glucagon-Like Peptide-1 (GLP-1) Agonists in the Management of Type 2 Diabetes and Associated Metabolic Disorders.胰高血糖素样肽-1（GLP-1）激动剂在2型糖尿病及相关代谢紊乱管理中的最新进展和治疗益处
Cureus. 2024 Oct 21;16(10):e72080. doi: 10.7759/cureus.72080. eCollection 2024 Oct.
8
Post Hoc Analysis of SURPASS-1 to -5: Efficacy and Safety of Tirzepatide in Adults with Type 2 Diabetes are Independent of Baseline Characteristics.SURPASS-1至-5的事后分析：替尔泊肽在2型糖尿病成人患者中的疗效和安全性与基线特征无关。
Diabetes Ther. 2025 Jan;16(1):43-71. doi: 10.1007/s13300-024-01660-0. Epub 2024 Nov 12.
9
Safe Continuation of Glucagon-like Peptide 1 Receptor Agonists at Endoscopy: A Case Series of 57 Adults Undergoing Endoscopic Sleeve Gastroplasty.经内镜袖状胃切除术的 57 例成人患者中胰高血糖素样肽 1 受体激动剂安全续贯应用：病例系列研究
Obes Surg. 2024 Jul;34(7):2369-2374. doi: 10.1007/s11695-024-07278-2. Epub 2024 May 16.

本文引用的文献

1
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2022.2. 糖尿病的分类和诊断：2022 年糖尿病医疗护理标准。
Diabetes Care. 2022 Jan 1;45(Suppl 1):S17-S38. doi: 10.2337/dc22-S002.
2
11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes-2022.11. 慢性肾脏病与风险管理：糖尿病医学诊疗标准-2022 年版。
Diabetes Care. 2022 Jan 1;45(Suppl 1):S175-S184. doi: 10.2337/dc22-S011.
3
6. Glycemic Targets: Standards of Medical Care in Diabetes-2022.6. 血糖目标：2022 年糖尿病医学护理标准。
Diabetes Care. 2022 Jan 1;45(Suppl 1):S83-S96. doi: 10.2337/dc22-S006.
4
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022.9. 血糖治疗的药物学方法：《2022 年糖尿病医学诊疗标准》。
Diabetes Care. 2022 Jan 1;45(Suppl 1):S125-S143. doi: 10.2337/dc22-S009.
5
Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice.管理肥胖症中 GLP-1 受体激动剂的胃肠道副作用：临床实践建议。
Postgrad Med. 2022 Jan;134(1):14-19. doi: 10.1080/00325481.2021.2002616. Epub 2021 Nov 29.
6
Maintenance of glycaemic control with liraglutide versus oral antidiabetic drugs as add-on therapies in patients with type 2 diabetes uncontrolled with metformin alone: A randomized clinical trial in primary care (LIRA-PRIME).利拉鲁肽对比二甲双胍单药治疗控制不佳的 2 型糖尿病患者的口服降糖药作为附加疗法的血糖控制维持：初级保健中的一项随机临床试验（LIRA-PRIME）。
Diabetes Obes Metab. 2022 Feb;24(2):204-211. doi: 10.1111/dom.14566. Epub 2021 Oct 18.
7
Glucagon-like Peptide-1 Receptor Agonists and the Risk of Acute Kidney Injury: Alarming, or Not?胰高血糖素样肽-1受体激动剂与急性肾损伤风险：令人担忧，还是并非如此？
Kidney Med. 2021 Jun 26;3(4):674-675. doi: 10.1016/j.xkme.2021.02.014. eCollection 2021 Jul-Aug.
8
CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries.CAPTURE 研究：13 个国家的 2 型糖尿病成人心血管疾病患病率的跨国、横断面研究。
Cardiovasc Diabetol. 2021 Jul 27;20(1):154. doi: 10.1186/s12933-021-01344-0.
9
Historical HbA Values May Explain the Type 2 Diabetes Legacy Effect: UKPDS 88.既往糖化血红蛋白（HbA）值或可解释2型糖尿病遗留效应：英国前瞻性糖尿病研究（UKPDS）88
Diabetes Care. 2021 Jul 7;44(10):2231-7. doi: 10.2337/dc20-2439.
10
Increased Hemoglobin A Time in Range Reduces Adverse Health Outcomes in Older Adults With Diabetes.血红蛋白 A1c 时间达标率提高可降低老年糖尿病患者的不良健康结局。
Diabetes Care. 2021 Aug;44(8):1750-1756. doi: 10.2337/dc21-0292. Epub 2021 Jun 14.